Morgan Stanley on Ascendis Pharma (ASND): 'we view Yuviwel’s approval as a positive inflection for Ascendis'
Tweet Send to a Friend
Morgan Stanley analyst Maxwell Skor reiterated an Overweight rating and $256.00 price target on Ascendis Pharma (NASDAQ: ASND).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
